The Bundibugyo Ebola death toll moved from eighty on Tuesday to one hundred thirty-six on Wednesday — fifty-six deaths in three days, in an outbreak the WHO declared a Public Health Emergency of International Concern on Monday [1]. The vaccine the world does have, Ervebo, does not cover this strain. The candidate that does is at least two months from a field deployment [2].

The May 20 lead in this paper called the Bundibugyo outbreak a three-week cartridge silence with a name. The field lab in Bunia had been testing for the wrong Ebola because the cartridge it had on the shelf was the wrong assay. The feature that ran alongside the lead carried that gap back to one health officer's flight from Bunia. Thursday morning the gap is a body count.

It is also still a contradiction the U.S. has not withdrawn. The CDC's Title 42 order against arrivals from the affected districts went up Monday. The WHO's instruction that "no country should close borders" was issued the same day. The paper's Tuesday brief on that collision noted it had not been publicly defended; forty-eight hours later, it still has not been.

What households can do in the meantime is the short list health writers usually run on day two. Wash hands with soap and running water; bleach surfaces after contact with an unwell traveller; do not touch the dead without protection; report fever after recent travel from North Kivu or Ituri to a clinic, not a household elder. Burials in the affected districts should be supervised. Ervebo will not help against this strain, so its presence in a country's stockpile is not a reason to relax other measures [3]. Pregnant household members should be screened at the first sign of fever; survivors should be told that semen and breast milk can carry virus for months [4].

What the field is missing is not service knowledge. It is the cartridge supply, the rapid-test inventory, the contact-tracing manpower, and a vaccine — and the vaccine is the longest line item. A monovalent Bundibugyo candidate exists in pre-clinical and small-scale clinical work. None of the trial sponsors has put a date on field deployment shorter than eight to twelve weeks from the activation of an outbreak response. The CBS and Associated Press write-throughs both quote that window without naming a sponsor [2][5]. The New York Times treats the absence as the medical story: "there is no vaccine and no treatment for this strain" [4]. AP's Africa file quotes the WHO Africa office on the scale-up of testing and contact tracing while noting the same vaccine gap [5]. The WHO Africa office's own statement, posted to its country page Monday, is the institutional record of the scale-up — and confirms which strain the field is dealing with [6].

The 136 number, like the 80 number before it, is a moving count. It will continue to move because the inputs are unchanged: the right cartridges are still being shipped in, the candidate vaccine is still in development, and the border the U.S. has closed is the one of the few borders WHO did not want closed. Day two of a PHEIC, in other words, looks like day one, only with more deaths.

What a clinician reading this on a Thursday morning in Chicago or Lagos should take away is simple. Surveillance, not panic, is the work. A patient with fever and recent eastern-DRC travel needs to be asked the travel question at triage. The WHO is asking countries to keep borders open and screening tight. The CDC's order does the opposite, and that order is now an artifact of the policy contradiction the paper named on Monday. If it changes in either direction — withdrawn, modified, or formally defended — it will be the second institutional receipt this outbreak has produced. The first was the cartridge.

The 136 patients are the third.

-- NORA WHITFIELD, Chicago